About this trial
Fluid resuscitation is one of the cornerstones of treatment in ICU patients. Nonetheless, excessive fluid administration can lead to fluid overload which has been associated with worse outcomes in the ICU. To prevent this, assessments of fluid responsiveness are commonly employed. However, fluid responsiveness does not take fluid tolerance into account. Fluid tolerance is the idea that a patient might still be fluid responsive but might already be at risk of the detrimental effects of fluid therapy. Recent developments in point of care ultrasound e.g. the Venous excess ultrasound might help identify patients at risk of fluid overload. However its association with patient relevant outcomes in the ICU remains unclear.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
all patients admitted to the ICU 18 years or older expected to stay in the ICU for more than 24 hours
Disqualifiers
any obstruction between the righ atrium and structures assessed by VExUS
a medical history of: Major cardiac shunts (e.g. atrial septum defect), Tricuspid regurgitation, dialysis, portal hypertension, pulmonary hypertension, interstitial lung disease, recipients of a kidney of liver transplant.
patients in whom an ultrasound assesment is unfeasible e.g. a BMI over 40
Trial population
All cricitally ill patients who are expected to be admitted to the ICU for more than 24 hours and who do not meet the exclusion criteria
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Rate of acute kidney injury
Clinically relevant acute kidney injury in the ICU: a 200% rise in creatinine or the use of renal replacement therapy
Mortality
death of all causes
Rate of MAKE-30
a composite endpoint of mortality and acute kidney injury ( including renal replacement therapy)
Other outcomes
Lung ultrasound score
a score for lung aeration as assessed by ultrasound ranging from 0 to 36 where 0 is the normal physiological state
Cardiac function as assed by ultrasound
determined by eyeballing and measurement of the tricuspid annular plane systolic excursion (\>16 is normal)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.